Skip to content

Clinical trials

Phase 3 Lymphoma, Large B-Cell, Diffuse trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lymphoma, Large B-Cell, Diffuse Phase: Phase 3 Country / region: United States Clear all

70 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20004
20011
20023
20034
20041
20051
20063
20074
20084
20091
20102
20113
20121
20132
20152
20161
20171
20182
20191
20204
20213
20232
20241
20251
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed45
Terminated10
Active, not recruiting9
Recruiting3
Unknown status2
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fred Hutchinson Cancer Center5
Hoffmann-La Roche4
Genmab3
Jonsson Comprehensive Cancer Center3
Memorial Sloan Kettering Cancer Center3
Alliance for Clinical Trials in Oncology2
Janssen Research & Development, LLC2
M.D. Anderson Cancer Center2
Mayo Clinic2
Novartis Pharmaceuticals2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lymphoma, Large B-Cell, Diffuse70
Lymphoma, Non-Hodgkin41
Lymphoma40
Lymphoma, Follicular34
Lymphoma, Large-Cell, Immunoblastic32
Leukemia, Lymphocytic, Chronic, B-Cell31
Lymphoma, Mantle-Cell31
Burkitt Lymphoma30
Hodgkin Disease27
Lymphoma, B-Cell, Marginal Zone27

Trials

Showing 1 to 25 of 70. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.